Galantamine drug to treat metabolic syndrome, type 2 diabetes and heart disease
A study by the researchers shows 25 percent reduction in inflammation-related metabolic syndrome such as heart disease and type 2 diabetes (T2D) with a galantamine, a drug used to treat Alzheimer's disease. The galantamine drug fights with metabolic syndrome in reducing risks associated with type 2 diabetes (T2D) and heart diseases. There are no approved medications or drugs to treat metabolic syndrome. Currently, health care professionals prescribe lifestyle changes, treatments and drugs to treat individual conditions of metabolic syndrome such as high blood pressure (BP) or hypertension, high blood sugar or glucose levels or type 2 diabetes (T2D), excess body fat and cholesterol levels.
Researchers found anti-inflammatory properties of galantamine drug while conducting experiments on mice models. Researchers say this drug targets nervous system (which affects metabolic processes and digestion) including vagus nerve (which affects inflammation levels in the body) in treating the human metabolic syndrome. Safety trials are not required as this drug was already approved to treat Alzheimer's disease and safety of this drug was already established.
Researchers conducted double-blind placebo trials of 60 type 2 diabetes (T2D) individuals. They divided the participants into two groups. They gave galantamine to one group of individuals and placebo to another group of individuals for over 12 weeks duration. They analyzed the participant's heartbeat, cholesterol levels, insulin resistance, insulin levels, body weight and other inflammation markers. Their study shows marked reduction in the inflammatory markers in the blood, lower insulin levels and lower insulin resistance in galantamine group of individuals compared with the placebo group of individuals. But the study found insignificant differences in HDL and LDL cholesterol levels, body fat and weight changes.
Co-authors of the study were Dr. Yael Tobi Harris, chief of endocrinology, diabetes and metabolism, Long Island Jewish Medical Center, New York and Dr. Valentin A Pavlov, PhD, an associate professor, Feinstein Institute for Medical Research, Manhasset, New York, United States. The study findings were published in the JCI Insight. Title of the article was "Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial."
Lorcaserin reduces high blood sugar levels and increases insulin sensitivity in patients with type 2 diabetes
A study by the researchers from the Rowett Institute, the University of Aberdeen, Aberdeen, Scotland shows a significant reduction in blood sugar or glucose levels in patients with type 2 diabetes (T2D) with lorcaserin drug. Currently, lorcaserin has been used to treat obesity. This drug acts by modifying the activity of neurons in the brain which regulates hungriness. The study shows usage of lorcaserin drug reduces blood sugar or glucose levels and increases insulin sensitivity of the cells in patients with type 2 diabetes (T2D).
This medication targets pro-opiomelanocortin (POMC) hormones in the brain in regulating the appetite and to provide therapeutic benefits to patients with type 2 diabetes (T2D). This drug costs around US $215 for a month supply. Researchers say their study shows new treatment options to treat type 2 diabetes (T2D). But they say more research was needed with lorcaserin drug. Lead author of the study was Professor Lora K Heisler, The Rowett Institute, University of Aberdeen, Aberdeen, Scotland. The study findings were published in the Molecular Metabolism. Title of the article was "Lorcaserin improves glycemic control via a melanocortin neurocircuit."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.